38
Participants
Start Date
May 31, 2004
Primary Completion Date
March 31, 2008
Study Completion Date
March 31, 2008
ALVAC-CMV (vCP260)
"ALVAC-pp65 (vCP260), an attenuated canary pox-based vaccine (Aventis Sanofi Pasteur, Lyon, France), 3 doses (1.0 ml each) delivered intramuscularly in the deltoid muscle.~Sero-negative subjects will receive a total of 3 immunizations to be given day 0, 5 and 10.~Sero-positive subjects will receive a total of 2 immunizations to be given day 0 and 5. (Protocol amendment after findings from the 9/6/2006 interim analysis demonstrated that in the sero-positive group, only 2 vaccinations were required to generate maximum immune response.)"
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
National Heart, Lung, and Blood Institute (NHLBI)
NIH